Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly

Neuroradiology. 2016 Nov;58(11):1057-1065. doi: 10.1007/s00234-016-1728-4. Epub 2016 Aug 11.

Abstract

Introduction: The difficulty of predicting the efficacy of somatostatin analogs (SSA) is not fully resolved. Here, we quantitatively evaluated the predictive value of relative signal intensity (rSI) on T1- and T2-weighted magnetic resonance imaging (MRI) for the short-term efficacy (3 months) of SSA therapy in patients with active acromegaly and assessed the correlation between MRI rSI and expression of somatostatin receptors (SSTR).

Methods: This was a retrospective review of prospectively recorded data. Ninety-two newly diagnosed patients (37 males and 55 females) with active acromegaly were recruited. All patients were treated with pre-surgical SSA, followed by reassessment and transspenoidal surgery. rSI values were generated by calculating the ratio of SI in the tumor to the SI of normal frontal white matter. The Youden indices were calculated to determine the optimal cutoff of rSI to determine the efficacy of SSA. The correlation between rSI and expression of SSTR2/5 was analyzed by the Spearman rank correlation coefficient.

Results: T2 rSI was strongly correlated with biochemical sensitivity to SSA. The cutoff value of T2 rSI to distinguish biochemical sensitivity was 1.205, with a positive predictive value (PPV) of 81.5 % and a negative predictive value (NPV) of 77.3 %. No correlation was found between MRI and tumor size sensitivity. Moreover, T2 rSI was negatively correlated with the expression of SSTR5.

Conclusion: T2 rSI correlates with the expression of SSTR5 and quantitatively predicts the biochemical efficacy of SSA in acromegaly.

Keywords: Acromegaly; Magnetic resonance imaging; Relative signal intensity; Somatostatin analog; Somatostatin receptor.

MeSH terms

  • Acromegaly / diagnostic imaging*
  • Acromegaly / drug therapy*
  • Acromegaly / surgery
  • Adult
  • Drug Monitoring / methods*
  • Female
  • Growth Hormone-Secreting Pituitary Adenoma / diagnostic imaging*
  • Growth Hormone-Secreting Pituitary Adenoma / drug therapy*
  • Growth Hormone-Secreting Pituitary Adenoma / pathology
  • Humans
  • Image Interpretation, Computer-Assisted / methods
  • Magnetic Resonance Imaging / methods*
  • Male
  • Middle Aged
  • Reproducibility of Results
  • Retrospective Studies
  • Sensitivity and Specificity
  • Somatostatin / administration & dosage*
  • Treatment Outcome

Substances

  • Somatostatin